Clinical Trials for Liver Cancer

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLT012 in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with RECIST-measurable advanced solid tumors (excluding primary CNS malignancies), ECOG 0–1, adequate organ function, and controlled/treated CNS disease (if present) after standard therapies are eligible. Patients receive PLT012 IV every 3 weeks, a first-in-class humanized anti-CD36 IgG4 “metabolic checkpoint” monoclonal antibody intended to block CD36-mediated lipid uptake and restore antitumor T-cell function, with treatment continuing until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07337525

ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients <30 years with unresectable, relapsed/refractory solid tumors requiring accessible biopsy (Part 2 enriched for fibrolamellar carcinoma; also HCC, DSRCT, and non-CNS malignant rhabdoid tumor), this single-arm study evaluates a 21-day regimen of metronomic oral cyclophosphamide plus PK-guided oral sorafenib (multikinase inhibitor of RAF/VEGFR/PDGFR) with IV bevacizumab (anti–VEGF-A) and IV atezolizumab (anti–PD-L1 checkpoint inhibitor) every 21 days. The trial focuses on safety/RP2D and preliminary response with sorafenib exposure targeting to reduce variability/toxicity.

ClinicalTrials.gov ID: NCT05468359

A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients ≥12 years with unresectable/metastatic fibrolamellar hepatocellular carcinoma or adults with other solid tumors harboring the DNAJB1‑PRKACA fusion, including checkpoint‑naïve and some checkpoint‑experienced FLC cohorts. Treatment combines an off‑the‑shelf DNAJB1‑PRKACA junction neoepitope peptide vaccine (adjuvanted with TLR1/2 agonist XS15) with nivolumab (PD‑1 inhibitor) and ipilimumab (CTLA‑4 inhibitor) to augment vaccine‑primed T‑cell responses; a re‑enrollment option may use nivolumab plus vaccine if prior CTLA‑4 toxicity.

ClinicalTrials.gov ID: NCT04248569

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (1–21 years) with relapsed/refractory, AFP-high (≥100 ng/mL), HLA-A2–positive hepatoblastoma, HCN-NOS, or HCC receive a single infusion of autologous ET140203 T cells after lymphodepletion. ET140203 (JWATM-203) is an engineered T-cell therapy using an ARTEMIS receptor with a TCR-mimic that targets AFP158–166/HLA-A*02:01 to selectively kill AFP+/HLA-A2+ liver cancer cells.

ClinicalTrials.gov ID: NCT04634357